New stock news | Henmi Pharmaceutical plans to list in Hong Kong. The China Securities Regulatory Commission requires further clarification on the detailed situation of the previous A-share listing guidance filing.

On August 1st, the China Securities Regulatory Commission (CSRC) issued the "Supplementary Materials Requirements for Overseas Issuance and Listing Filing (July 25, 2025 to July 31, 2025)", and the CSRC International Department requested supplementary materials from 9 companies. In the announcement, the CSRC requested that HeMei Pharmaceuticals provide detailed information on the previous A-share listing counseling filing, whether there are plans to continue with the A-share listing and specific arrangements, and whether there are any significant impacts on this issuance and listing. According to the Hong Kong Stock Exchange's disclosure on May 29th, Ganzhou HeMei Pharmaceuticals Co., Ltd. submitted a listing application to the Hong Kong Stock Exchange Main Board. The CSRC requested HeMei Pharmaceuticals to provide clarification on the following matters and to have lawyers verify and provide clear legal opinions: 1. Please provide details on the company's previous A-share listing counseling filing, whether there are plans to continue with the A-share listing and specific arrangements, and whether there are any significant impacts on this issuance and listing. 2. Regarding the company's historical evolution, please explain: (1) the conclusion of compliance with legal and regulatory procedures for foreign exchange registration, overseas investment, foreign investment, and tax matters during the construction and dismantling of red-chip structures; (2) the conclusion of compliance with legal and regulatory procedures for the establishment of the company and all previous equity changes. 3. Regarding the company's employee shareholding plan, please provide a conclusion on its lawful and compliant implementation. 4. Please explain the explicit basis for the company and its subsidiaries' business scope not involving areas covered by the "Special Administrative Measures for Foreign Investment Access (Negative List) (2024 Edition)". According to the prospectus, HeMei Pharmaceuticals was established in 2002 and is an innovative biopharmaceutical company dedicated to discovering and developing small molecule drugs for autoimmune diseases and tumors, and is at the forefront of the industry in treating psoriasis, Behet's disease, inflammatory bowel disease, and innovative chemical therapies. As of May 21, 2025, HeMei Pharmaceuticals has developed seven small molecule candidate drugs targeting high unmet needs in autoimmune and tumor diseases. As of May 21, 2025, four of these candidate drugs are in Phase II, III clinical trials, or NDA stages and are applicable to 12 indications. One of HeMei Pharmaceuticals' core products, Mufemilast, is a novel small molecule phosphodiesterase 4B (PDE4B) protein expression blocker and PDE4 inhibitor with broad potential for treating autoimmune diseases. According to Frosst Sullivan, Mufemilast may be a globally unique drug with a dual mechanism of action: it can block the expression of the PDE4B protein and inhibit the activity of PDE4.